1. ALLA AKTIER
  2. NYHETER
  3. SEDANA MEDICAL

Sedana Medical

Nyheter Sedana Medical Nyheter alla bolag
Affiliate
Courtagefri handel på Nordnet till sista juni 2027! Har du inget konto på Nordnet så är det verkligen läge att skaffa ett. Just nu får nya kunder courtagefri handel till sista juni 2027. Läs mer om erbjudandet och skapa ditt konto här
Erbjudandet gäller nya kunder och omfattar handel via Nordnets app eller hemsida i nordiska aktier, ETF:er, teckningsrätter och teckningsoptioner. För fullständiga villkor se nordnet.se/jubileum. Kom ihåg att investeringar alltid innebär en risk.

Sedana Medical publishes its Annual Report for 2024

REG

Sedana Medical AB (publ) publishes its Annual Report for 2024. The Annual Report describes important events and financial information for 2024, as well as the progress the company has made on its strategic priorities during the year.

“Sedana Medical had a successful 2024 in which we achieved our goals in our three priority areas: We are very pleased to have achieved positive topline results for both of our pivotal clinical studies in the United States; with 17% sales growth we report our highest sales ever; and we delivered positive EBITDA for our ex-US operations in both Q1 and Q4 2024, after adjusting for one-off costs.", says Johannes Doll, President and CEO of Sedana Medical.
 
The Annual Report is available at www.sedanamedical.com.

For additional information, please contact:

Johannes Doll, CEO, +46 (0)76 303 66 66
Johan Spetz, CFO, +46 (0)730 36 37 89
ir@sedanamedical.com

This information is information that Sedana Medical AB (publ) is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication, through the agency of the contact persons set out above, at 2025-04-10 17:32 CEST.

About Sedana Medical

Sedana Medical AB (publ) is a pioneer medtech and pharmaceutical company focused on inhaled sedation to improve the patient’s life during and beyond sedation. Through the combined strengths of the medical device Sedaconda ACD and the pharmaceutical Sedaconda (isoflurane), Sedana Medical provides inhaled sedation for mechanically ventilated patients in intensive care.

Sedana Medical has direct sales in Benelux, France, Germany, Great Britain, the Nordics, and Spain. In other parts of Europe as well as in Asia, Australia, Canada, and South- and Central America, the company works with external distributors.

Sedana Medical was founded in 2005, is listed on Nasdaq Stockholm (SEDANA) and headquartered in Stockholm, Sweden.

Attachments

Sedana AR 2024 ENG
sedanamedicalab-2024-12-31-0-sv (2)

Datum 2025-04-10, kl 17:32
Källa MFN
Bifogade filer
Sedana AR 2024 ENG
sedanamedicalab-2024-12-31-0-sv (2)